BBIO — BridgeBio Pharma Income Statement
0.000.00%
Last trade - 00:00
- $5.43bn
- $6.74bn
- $9.30m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 40.6 | 8.25 | 69.7 | 77.6 | 9.3 |
Cost of Revenue | |||||
Gross Profit | 38.1 | 8.25 | 66.6 | 74.2 | 6.86 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 307 | 483 | 646 | 590 | 617 |
Operating Profit | -267 | -474 | -577 | -512 | -607 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -289 | -505 | -586 | -485 | -653 |
Net Income After Taxes | -289 | -505 | -586 | -485 | -653 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -261 | -449 | -563 | -481 | -643 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -261 | -449 | -563 | -481 | -643 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.46 | -3.8 | -3.9 | -2.97 | -3.9 |